United States· US:0003-0895_9d2e509f-3c81-45c7-984b-4e3c8b56dbef
SOTYKTU
A deucravacitinib product containing deucravacitinib, registered in United States by E.R. Squibb & Sons, L.L.C.. The same ATC class is registered in 12 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Deucravacitinib is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AF07 (deucravacitinib), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 7 of them publish a price we can compare per daily dose
Deucravacitinib · ATC L04AF07
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of deucravacitinib costs, country by country.
Normalised to the WHO defined daily dose (6 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Deucravacitinib · price per daily dose (6 mg)
USD · FX 28 Sept 2026
- FR France$22.97
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- DEUCRAVACITINIB
- Manufacturer
- E.R. Squibb & Sons, L.L.C.
- Country
- United States (US)
- ATC code
- L04AF07
- ATC class
- Deucravacitinib
- Defined daily dose
- 6 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- July 12, 2026
Packs & prices · 4
- ndc110003-0895-11
- ndc110003-0895-91
- ndc11000308951130 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0003-0895-11)
- ndc11000308959130 TABLET, FILM COATED in 1 BLISTER PACK (0003-0895-91)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Deucravacitinib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSOTYKTUBristol-Myers Squibb Pharma EEIG, Dublin
- SpainSOTYKTU 6 MG COMPRIMIDOS RECUBIERTOS CON PELICULABristol-Myers Squibb Pharma Eeig
- FinlandSOTYKTUBristol-Myers Squibb Pharma EEIG
- FranceSOTYKTU 6 mg, comprimé pelliculéBRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- IrelandSOTYKTU 6 mg Film-coated tabletBristol-Myers Squibb Pharma EEIG
- IcelandSOTYKTUBristol-Myers Squibb Pharma EEIG*
- NetherlandsSOTYKTU 6 mg filmomhulde tablettenBristol-Myers Squibb Pharma EEIG
- NorwaySotyktuBristol-Myers Squibb Pharma EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Sotyktu
- Liechtenstein · Sotyktu
- Norway · Sotyktu
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a075cffb-5aa5-479b-bbad-b3b29be1b29a GET /v1/drugs/a075cffb-5aa5-479b-bbad-b3b29be1b29a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "6",
"substance": "DEUCRAVACITINIB",
"productndc": "0003-0895",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA214958",
"marketing_category": "NDA"
}See everything about deucravacitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.